Combination therapy with antibiotics and isotype selective PI3K inhibitors has the potential of increasing therapeutic outcome of drug resistant bacterial infections without interfering with PI3Ks in other cell types leading to unwanted side effects. The gene discussed is PIK3CD; the disease is bacterial infectious disease.